Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health ...

Seventeen states sued the Department of Health and Human Services in 2024, alleging that a landmark disability law was ...

Anthony Fauci is working on a book, we unpack Trump's latest drug pricing deals, and more from STAT's D.C. Diagnosis ...

For now, though, perhaps some headlines will suffice …  An experimental gene therapy for Angelman syndrome from Ultragenyx ...

Experts agreed that the biggest threat to progress on overdose deaths is the looming Medicaid cuts. Researchers at Penn’s ...

At a "practice of last resort," pediatricians prioritize allaying parents' vaccine concerns without hardline dismissals.

Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no ...

The whole of my field has been flattened into a single lazy question: Did the health care system fail her?” writes Jennifer ...

Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Eli Lilly said Tuesday it would buy ...

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of ...

News on rare diseases, including the development of new treatments, the challenges of diagnosis and treatment and the stories of patients and their families. The page features in-depth reporting on ...